Tectonic Therapeutic. TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group ...
PR No: C3309C S™icroelectronics Reports Q4 and FY 2024 Financial Results Q4 net revenues $3.32 billion; gross margin 37.7%;... PARIS--(BUSINESS WIRE)--Regulatory News:Maurel & Prom (Paris:MAU):M&P ...
Tenax Therapeutics said it will extend its Phase 3 clinical development of an oral form of levosimendan for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). Tenax ...
Kruse from Harvard Medical School. In January, the company shared positive early results from its Phase 1b clinical trial of TX45, its main product candidate. TX45 is a long-acting Fc-relaxin ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback